Telix Pharmaceuticals reports Q2 revenue of US$247M
- Telix recorded US$247 million in total group revenue for the second quarter of 2026.
- The company's shares closed flat at $15.10 prior to the announcement.
- Management projects full-year 2026 revenue to exceed US$1 billion.
Telix Pharmaceuticals (ASX:TLX) generated US$247 million in group revenue for the second quarter ended June 30, driven by expanding sales in its precision medicine unit.
The top-line total represents a 21% increase compared to the same period last year and a 7% gain over the previous quarter.
"We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio," said Telix Pharmaceuticals Managing Director and Group CEO Dr Christian Behrenbruch.
Precision medicine revenue rose 30% year-over-year to US$45 million in third-party sales.
Following the announcement, the Telix Pharmaceuticals share price was unchanged at $15.10.
The company stated that full-year 2026 revenue and other income are expected to surpass US$950 million, with a US$40 million payment from Regeneron.
In addition, research and development expenditure guidance for full-year 2026 was updated to US$270 million as the business advances its clinical radiopharmaceutical pipeline.
